New Live Attenuated Tuberculosis Vaccine MTBVAC Induces Trained Immunity and Confers Protection Against Experimental Lethal Pneumonia

Overview

Journal PLoS Pathog

Specialty Microbiology

Date 2020 Apr 3

PMID 32240273

Citations 37

Authors

Raquel Tarancon

Jorge Dominguez-Andres

Santiago Uranga

Anaisa V Ferreira

Laszlo A Groh

Mirian Domenech

Fernando Gonzalez-Camacho

Niels P Riksen

Nacho Aguilo

Jose Yuste

Carlos Martin

Mihai G Netea

Affiliations

Soon will be listed here.

Abstract

Among infectious diseases, tuberculosis is the leading cause of death worldwide, and represents a serious threat, especially in developing countries. The protective effects of Bacillus Calmette-Guerin (BCG), the current vaccine against tuberculosis, have been related not only to specific induction of T-cell immunity, but also with the long-term epigenetic and metabolic reprogramming of the cells from the innate immune system through a process termed trained immunity. Here we show that MTBVAC, a live attenuated strain of Mycobacterium tuberculosis, safe and immunogenic against tuberculosis antigens in adults and newborns, is also able to generate trained immunity through the induction of glycolysis and glutaminolysis and the accumulation of histone methylation marks at the promoters of proinflammatory genes, facilitating an enhanced response after secondary challenge with non-related bacterial stimuli. Importantly, these findings in human primary myeloid cells are complemented by a strong MTBVAC-induced heterologous protection against a lethal challenge with Streptococcus pneumoniae in an experimental murine model of pneumonia.

Citing Articles

PBMC and fibroblast cocultures to mimic the effect of BCG on trained immunity.

Merriam D, Weinberg A MicroPubl Biol. 2025; 2025.

PMID: 39981222 PMC: 11840551. DOI: 10.17912/micropub.biology.001449.

Tuberculosis vaccines and therapeutic drug: challenges and future directions.

An Y, Ni R, Zhuang L, Yang L, Ye Z, Li L Mol Biomed. 2025; 6(1):4.

PMID: 39841361 PMC: 11754781. DOI: 10.1186/s43556-024-00243-6.

The cholera toxin B subunit induces trained immunity in dendritic cells and promotes CD8 T cell antitumor immunity.

Tepale-Segura A, Gajon J, Munoz-Cruz S, Castro-Escamilla O, Bonifaz L Front Immunol. 2024; 15:1362289.

PMID: 38812523 PMC: 11133619. DOI: 10.3389/fimmu.2024.1362289.

Low-dose infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates.

Peralta Alvarez M, Jones H, Azema H, Davis C, White A, Sarfas C Front Immunol. 2024; 15:1387454.

PMID: 38799468 PMC: 11116990. DOI: 10.3389/fimmu.2024.1387454.

Tuberculosis vaccine developments and efficient delivery systems: A comprehensive appraisal.

Hoseinpour R, Hasani A, Baradaran B, Abdolalizadeh J, Salehi R, Hasani A Heliyon. 2024; 10(4):e26193.

PMID: 38404880 PMC: 10884459. DOI: 10.1016/j.heliyon.2024.e26193.

References

Cernuschi T, Malvolti S, Nickels E, Friede M . Bacillus Calmette-Guérin (BCG) vaccine: A global assessment of demand and supply balance. Vaccine. 2017; 36(4):498-506. PMC: 5777639. DOI: 10.1016/j.vaccine.2017.12.010. View

Houben R, Dodd P . The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med. 2016; 13(10):e1002152. PMC: 5079585. DOI: 10.1371/journal.pmed.1002152. View

Arts R, Carvalho A, La Rocca C, Palma C, Rodrigues F, Silvestre R . Immunometabolic Pathways in BCG-Induced Trained Immunity. Cell Rep. 2016; 17(10):2562-2571. PMC: 5177620. DOI: 10.1016/j.celrep.2016.11.011. View

Gonzalo-Asensio J, Marinova D, Martin C, Aguilo N . MTBVAC: Attenuating the Human Pathogen of Tuberculosis (TB) Toward a Promising Vaccine against the TB Epidemic. Front Immunol. 2018; 8:1803. PMC: 5736532. DOI: 10.3389/fimmu.2017.01803. View

Benn C, Netea M, Selin L, Aaby P . A small jab - a big effect: nonspecific immunomodulation by vaccines. Trends Immunol. 2013; 34(9):431-9. DOI: 10.1016/j.it.2013.04.004. View

Bekkering S, Arts R, Novakovic B, Kourtzelis I, van der Heijden C, Li Y . Metabolic Induction of Trained Immunity through the Mevalonate Pathway. Cell. 2018; 172(1-2):135-146.e9. DOI: 10.1016/j.cell.2017.11.025. View

van der Poll T, Opal S . Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. 2009; 374(9700):1543-56. DOI: 10.1016/S0140-6736(09)61114-4. View

Etchegaray J, Mostoslavsky R . Interplay between Metabolism and Epigenetics: A Nuclear Adaptation to Environmental Changes. Mol Cell. 2016; 62(5):695-711. PMC: 4893201. DOI: 10.1016/j.molcel.2016.05.029. View

Dominguez-Andres J, Joosten L, Netea M . Induction of innate immune memory: the role of cellular metabolism. Curr Opin Immunol. 2018; 56:10-16. DOI: 10.1016/j.coi.2018.09.001. View

10.

Andrews N, Waight P, Burbidge P, Pearce E, Roalfe L, Zancolli M . Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014; 14(9):839-46. DOI: 10.1016/S1473-3099(14)70822-9. View

11.

Redelman-Sidi G, Glickman M, Bochner B . The mechanism of action of BCG therapy for bladder cancer--a current perspective. Nat Rev Urol. 2014; 11(3):153-62. DOI: 10.1038/nrurol.2014.15. View

12.

Sable S, Posey J, Scriba T . Tuberculosis Vaccine Development: Progress in Clinical Evaluation. Clin Microbiol Rev. 2019; 33(1). PMC: 6822991. DOI: 10.1128/CMR.00100-19. View

13.

Brosch R, Gordon S, Garnier T, Eiglmeier K, Frigui W, Valenti P . Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A. 2007; 104(13):5596-601. PMC: 1838518. DOI: 10.1073/pnas.0700869104. View

14.

Arts R, Moorlag S, Novakovic B, Li Y, Wang S, Oosting M . BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. Cell Host Microbe. 2018; 23(1):89-100.e5. DOI: 10.1016/j.chom.2017.12.010. View

15.

Ladhani S, Collins S, Djennad A, Sheppard C, Borrow R, Fry N . Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis. 2018; 18(4):441-451. DOI: 10.1016/S1473-3099(18)30052-5. View

16.

Alvarez-Arguedas S, Uranga S, Martin M, Elizalde J, Gomez A, Julian E . Therapeutic efficacy of the live-attenuated Mycobacterium tuberculosis vaccine, MTBVAC, in a preclinical model of bladder cancer. Transl Res. 2018; 197:32-42. DOI: 10.1016/j.trsl.2018.03.004. View

17.

Tameris M, Mearns H, Penn-Nicholson A, Gregg Y, Bilek N, Mabwe S . Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. Lancet Respir Med. 2019; 7(9):757-770. DOI: 10.1016/S2213-2600(19)30251-6. View

18.

Novakovic B, Habibi E, Wang S, Arts R, Davar R, Megchelenbrink W . β-Glucan Reverses the Epigenetic State of LPS-Induced Immunological Tolerance. Cell. 2016; 167(5):1354-1368.e14. PMC: 5927328. DOI: 10.1016/j.cell.2016.09.034. View

19.

Saeed S, Quintin J, Kerstens H, Rao N, Aghajanirefah A, Matarese F . Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science. 2014; 345(6204):1251086. PMC: 4242194. DOI: 10.1126/science.1251086. View

20.

Clark S, Lanni F, Marinova D, Rayner E, Martin C, Williams A . Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against Tuberculosis. J Infect Dis. 2017; 216(5):525-533. DOI: 10.1093/infdis/jix030. View